Identification of candidate genes associated with tubal origin of high‑grade serous ovarian cancer

Xiang,Li; Rong,Guohua; Zhao,Jing; Wang,Zhenyan; Shi,Fengfeng

doi:10.3892/ol.2018.8346

Identification of candidate genes associated with tubal origin of high‑grade serous ovarian cancer

Authors:
- Li Xiang
- Guohua Rong
- Jing Zhao
- Zhenyan Wang
- Fengfeng Shi
View Affiliations

Affiliations: Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Breast Surgery, Qingdao Municipal Hospital (Group), Qingdao, Shandong 266000, P.R. China, Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China
Published online on: March 26, 2018 https://doi.org/10.3892/ol.2018.8346
Pages: 7769-7775
Copyright: © Xiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Evidence indicates that high‑grade serous ovarian carcinoma arises from the fallopian tube, rather than ovarian surface epithelium. This is termed the ‘tubal origin’ theory. The aim of the present study was to compare the immunophenotype and gene expression profiling among high‑grade serous ovarian carcinoma (HGSOC), fallopian tube epithelium (FTE) and ovarian surface epithelium (OSE) based on tubal origin theory, and identify the differential genes associated with ovarian carcinogenesis. A total of 61 cases of fresh tissue samples including 21 cases of HGSOC, 20 cases of OSE, and 20 cases of FTE were obtained following surgical resection. Immunostaining was performed to detect the expression of PAX8, which has been considered as a potential immunophenotype marker of Müllerian origin. Illumina BeadChip was applied for gene expression profiling. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed to confirm the differential expression of candidate genes between HGSOC and FTE. The results of the present study demonstrated that PAX8 was highly expressed in HGSOC (19/21, 90.4%) and FTE (20/20, 100%), but not in OSE (3/20, 14.3%). A dendrogram generated by cluster analysis indicated a higher similarity of gene expression profile between HGSOC and FTE than OSE. A total of 2,412 differentially expressed genes were identified (absolute fold change >2) between HGSOC and FTE, including 822 upregulated genes in cancer and 1,590 downregulated genes. S100 calcium binding protein P, Ras‑interacting protein 1, Wnt family member 5A, tumor‑associated calcium signal transducer 2, Dickkopf Wnt signaling pathway inhibitor 3 and tumor suppressor candidate 3 genes were identified as candidate markers, of which the differential gene expression in HGSOC and FTE was confirmed by RT‑qPCR (P<0.05). The results indicate the presence of a greater similarity in the immunophenotype and gene expression profile of HGSOC and FTE, when compared with OSE, which was consistent with the tubal origin theory of HGSOC.

View Figures

View References

1	Kujawa KA and Lisowska KM: Ovarian cancer-from biology to clinic. Postepy Hig Med Dosw (Online). 69:1275–1290. 2015.(Article in Polish). View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Eng KH, Hanlon BM, Bradley WH and Szender JB: Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. Gynecol Oncol. 139:228–235. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ramalingam P: Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer. Oncology (Williston Park). 30:166–176. 2016.PubMed/NCBI
6	Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S and Sehouli J: The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet. 293:695–700. 2016. View Article : Google Scholar : PubMed/NCBI
7	Kurman RJ: Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 24 Suppl 10:S16–S21. 2013. View Article : Google Scholar
8	Perets R and Drapkin R: It's totally Tubular…Riding the new wave of ovarian cancer research. Cancer Res. 76:10–17. 2016. View Article : Google Scholar : PubMed/NCBI
9	Ning G, Bijron JG, Yamamoto Y, Wang X, Howitt BE, Herfs M, Yang E, Hong Y, Cornille M, Wu L, et al: The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium. J Pathol. 234:478–487. 2014. View Article : Google Scholar : PubMed/NCBI
10	Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W and Crum CP: STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed). 3:625–634. 2011.PubMed/NCBI
11	Xiang L, Zheng W and Kong B: Detection of PAX8 and p53 is beneficial in recognizing metastatic carcinomas in pelvic washings, especially in cases with suspicious cytology. Gynecol Oncol. 127:595–600. 2012. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Dalta Dalta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Fathalla MF: Incessant ovulation-a factor in ovarian neoplasia? Lancet. 2:1631971. View Article : Google Scholar : PubMed/NCBI
14	Fraumeni JF Jr, Lloyd JW, Smith EM and Wagoner JK: Cancer mortality among nuns: Role of marital status in etiology of neoplastic disease in women. J Natl Cancer Inst. 42:455–468. 1969.PubMed/NCBI
15	Mhawech-Fauceglia P, Wang D, Samrao D, Godoy H, Ough F, Liu S, Pejovic T and Lele S: Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. Gynecol Oncol. 127:198–201. 2012. View Article : Google Scholar : PubMed/NCBI
16	Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW and Crum CP: The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 30:230–236. 2006. View Article : Google Scholar : PubMed/NCBI
17	Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS and Muto MG: Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 25:3985–3990. 2007. View Article : Google Scholar : PubMed/NCBI
18	Seidman JD: Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: A pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer). Int J Gynecol Pathol. 34:112–120. 2015. View Article : Google Scholar : PubMed/NCBI
19	Erickson BK, Conner MG and Landen CN Jr: The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 209:409–414. 2013. View Article : Google Scholar : PubMed/NCBI
20	Walker JL, Powell CB, Chen LM, Carter J, Jump Bae VL, Parker LP, Borowsky ME and Gibb RK: Society of gynecologic oncology recommendations for the prevention of ovarian cancer. Cancer. 121:2108–2120. 2015. View Article : Google Scholar : PubMed/NCBI
21	Duska LR and Kohn EC: The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol. 28 Suppl 8:2017. View Article : Google Scholar : PubMed/NCBI
22	Roche Long KC, Abu-Rustum NR, Nourmoussavi M and Zivanovic O: Risk-reducing salpingectomy: Let us be opportunistic. Cancer. 123:1714–1720. 2017. View Article : Google Scholar : PubMed/NCBI
23	Wang X, Tian T, Li X, Zhao M, Lou Y, Qian J, Liu Z, Chen H and Cui Z: High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancer. Am J Cancer Res. 5:2409–2421. 2015.PubMed/NCBI
24	Surowiak P, Maciejczyk A, Materna V, Drag-Zalesińska M, Wojnar A, Pudelko M, Kedzia W, Spaczyński M, Dietel M, Zabel M and Lage H: Unfavourable prognostic significance of S100P expression in ovarian cancers. Histopathology. 51:125–128. 2007. View Article : Google Scholar : PubMed/NCBI
25	Post A, Pannekoek WJ, Ross SH, Verlaan I, Brouwer PM and Bos JL: Rasip1 mediates Rap1 regulation of Rho in endothelial barrier function through ArhGAP29. Proc Natl Acad Sci USA. 110:11427–11432. 2013. View Article : Google Scholar : PubMed/NCBI
26	Arabzadeh S, Hossein G and Zarnani AH: Wnt5A exerts immunomodulatory activity in the human ovarian cancer cell line SKOV-3. Cell Biol Int. 40:177–187. 2016. View Article : Google Scholar : PubMed/NCBI
27	Jannesari-Ladani F, Hossein G, Monhasery N, Shahoei SH and Mood Izadi N: Wnt5a influences viability, migration, adhesion, colony formation, E- and N-cadherin expression of human ovarian cancer cell line SKOV-3. Folia Biol (Praha). 60:57–67. 2014.PubMed/NCBI
28	Shvartsur A and Bonavida B: Trop2 and its overexpression in cancers: Regulation and clinical/therapeutic implications. Genes Cancer. 6:84–105. 2015.PubMed/NCBI
29	Mohammadpour H, Pourfathollah AA, Zarif Nikougoftar M and Khalili S: Key role of Dkk3 protein in inhibition of cancer cell proliferation: An in silico identification. J Theor Biol. 393:98–104. 2016. View Article : Google Scholar : PubMed/NCBI
30	Kratochvílová K, Horak P, Ešner M, Souček K, Pils D, Anees M, Tomasich E, Dráfi F, Jurtíková V, Hampl A, et al: Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells. Int J Cancer. 137:1330–1340. 2015. View Article : Google Scholar : PubMed/NCBI